{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:41:39Z","timestamp":1791297699072,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T00:00:00Z","timestamp":1536364800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Roche Diagnostics K.K."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s10157-018-1639-2","type":"journal-article","created":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T06:53:49Z","timestamp":1536389629000},"page":"402-408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Biological variation of procalcitonin levels in hemodialysis patients"],"prefix":"10.1007","volume":"23","author":[{"given":"Shun","family":"Kubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Matsukane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0285-8388","authenticated-orcid":false,"given":"Nobuhiko","family":"Joki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,8]]},"reference":[{"key":"1639_CR1","first-page":"143-8","volume":"41","author":"IH Khan","year":"1993","unstructured":"Khan IH, Catto GR. Long-term complications of dialysis: infection. Kidney Int Suppl. 1993;41:143-8.","journal-title":"Kidney Int Suppl"},{"key":"1639_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1744-9987.2012.01144.x","volume":"17","author":"M Wakasugi","year":"2013","unstructured":"Wakasugi M, Kazama JJ, Yamamoto S, Kawamura K, Narita I. Cause-specific excess mortality among dialysis patients: comparison with the general population in Japan. Ther Apher Dial. 2013;17:298\u2013304.","journal-title":"Ther Apher Dial"},{"key":"1639_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1744-9987.2012.01143.x","volume":"16","author":"S Nakai","year":"2012","unstructured":"Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, et al. An overview of regular dialysis treatment in japan (as of 31 december 2010). Ther Apher Dial. 2012;16:483\u2013521.","journal-title":"Ther Apher Dial"},{"key":"1639_CR4","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1681\/ASN.2008010012","volume":"19","author":"AY Wang","year":"2008","unstructured":"Wang AY, Lai KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol. 2008;19:1643\u201352.","journal-title":"J Am Soc Nephrol"},{"key":"1639_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/nep.12063","volume":"18","author":"M Iwasaki","year":"2013","unstructured":"Iwasaki M, Joki N, Tanaka Y, Ikeda N, Hayashi T, Kubo S, et al. Efficacy of n-terminal pro-brain natriuretic peptide digit number for screening of cardiac disease in new haemodialysis patients. Nephrology (Carlton). 2013;18:497\u2013504.","journal-title":"Nephrology (Carlton)"},{"key":"1639_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/0886022X.2016.1256311","volume":"39","author":"M Iwasaki","year":"2017","unstructured":"Iwasaki M, Yamazaki K, Ikeda N, Tanaka Y, Hayashi T, Kubo S, et al. Point of care assessment of cardiac troponin t level in ckd patients with chest symptom. Renal Fail. 2017;39:166\u2013172","journal-title":"Renal Fail"},{"key":"1639_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/0140-6736(93)90277-N","volume":"341","author":"M Assicot","year":"1993","unstructured":"Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341:515\u20138.","journal-title":"Lancet"},{"key":"1639_CR8","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1097\/CCM.0B013E318165BABB","volume":"36","author":"KL Becker","year":"2008","unstructured":"Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36:941\u201352.","journal-title":"Crit Care Med"},{"key":"1639_CR9","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1097\/00003246-200205000-00025","volume":"30","author":"FJ Wiedermann","year":"2002","unstructured":"Wiedermann FJ, Kaneider N, Egger P, Tiefenthaler W, Wiedermann CJ, Lindner KH, Schobersberger W. Migration of human monocytes in response to procalcitonin. Crit Care Med. 2002;30:1112\u20137.","journal-title":"Crit Care Med"},{"key":"1639_CR10","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1093\/jac\/dks265","volume":"67","author":"JA Foushee","year":"2012","unstructured":"Foushee JA, Hope NH, Grace EE. Applying biomarkers to clinical practice: a guide for utilizing procalcitonin assays. J Antimicrob Chemother. 2012;67:2560\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"1639_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41100-016-0025-3","volume":"2","author":"TT Koji Ichihara","year":"2016","unstructured":"Koji Ichihara TT, Takahashi S, Matsukawa M, Yanase M, Kitamura H, Masumori N. Serum procalcitonin level in chronic hemodialytic patients with no evidence of bacterial infection. Renal Replace Ther. 2016;2:9.","journal-title":"Renal Replace Ther"},{"key":"1639_CR12","first-page":"411","volume":"73","author":"H Trimarchi","year":"2013","unstructured":"Trimarchi H, Dicugno M, Muryan A, Lombi F, Iturbe L, Rana MS, et al. Pro-calcitonin and inflammation in chronic hemodialysis. Medicina (B Aires). 2013;73:411\u20136.","journal-title":"Medicina (B Aires)"},{"key":"1639_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00003643-200102000-00004","volume":"18","author":"M Meisner","year":"2001","unstructured":"Meisner M, Lohs T, Huettemann E, Schmidt J, Hueller M, Reinhart K. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol. 2001;18:79\u201387.","journal-title":"Eur J Anaesthesiol"},{"key":"1639_CR14","first-page":"341","volume":"34","author":"B Quiroga","year":"2014","unstructured":"Quiroga B, Villaverde M, Vega A, Abad S, Reque J, Lopez-Gomez JM. Procalcitonin as an early predictor of acute infection in hemodialysis patients. Nefrologia. 2014;34:341\u20136.","journal-title":"Nefrologia"},{"key":"1639_CR15","first-page":"431859","volume":"2012","author":"K Mori","year":"2012","unstructured":"Mori K, Noguchi M, Sumino Y, Sato F, Mimata H. Use of procalcitonin in patients on chronic hemodialysis: procalcitonin is not related with increased serum calcitonin. ISRN Urol. 2012;2012:431859.","journal-title":"ISRN Urol"},{"key":"1639_CR16","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1681\/ASN.V451205","volume":"4","author":"JT Daugirdas","year":"1993","unstructured":"Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume kt\/v: an analysis of error. J Am Soc Nephrol. 1993;4:1205\u201313.","journal-title":"J Am Soc Nephrol"},{"key":"1639_CR17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3109\/10408363.2016.1150252","volume":"53","author":"F Braga","year":"2016","unstructured":"Braga F, Panteghini M. Generation of data on within-subject biological variation in laboratory medicine: an update. Crit Rev Clin Lab Sci. 2016;53:313\u201325.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"1639_CR18","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s11255-017-1710-z","volume":"49","author":"Y Sun","year":"2017","unstructured":"Sun Y, Jiang L, Shao X. Predictive value of procalcitonin for diagnosis of infections in patients with chronic kidney disease: a comparison with traditional inflammatory markers c-reactive protein, white blood cell count, and neutrophil percentage. Int Urol Nephrol. 2017;49:2205\u20132216","journal-title":"Int Urol Nephrol"},{"key":"1639_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11255-013-0542-8","volume":"46","author":"R Dumea","year":"2014","unstructured":"Dumea R, Siriopol D, Hogas S, Mititiuc I, Covic A. Procalcitonin. Diagnostic value in systemic infections in chronic kidney disease or renal transplant patients. Int Urol Nephrol. 2014;46:461\u20138.","journal-title":"Int Urol Nephrol"},{"key":"1639_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00134-003-1664-8","volume":"29","author":"AA Dahaba","year":"2003","unstructured":"Dahaba AA, Rehak PH, List WF. Procalcitonin and c-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med. 2003;29:579\u201383.","journal-title":"Intensive Care Med"},{"key":"1639_CR21","first-page":"297","volume":"15","author":"T Sitter","year":"2002","unstructured":"Sitter T, Schmidt M, Schneider S, Schiffl H. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. J Nephrol. 2002;15:297\u2013301.","journal-title":"J Nephrol"},{"key":"1639_CR22","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1046\/j.1523-1755.1999.00422.x","volume":"55","author":"P Stenvinkel","year":"1999","unstructured":"Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899\u2013911.","journal-title":"Kidney Int"},{"key":"1639_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1476-9255-9-17","volume":"9","author":"Y Tanaka","year":"2012","unstructured":"Tanaka Y, Joki N, Hase H, Iwasaki M, Ikeda M, Ando R, et al. Effect of erythropoietin-stimulating agent on uremic inflammation. J Inflamm (Lond). 2012;9:17.","journal-title":"J Inflamm (Lond)"},{"key":"1639_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.0300-9475.2005.01545.x","volume":"61","author":"S Herget-Rosenthal","year":"2005","unstructured":"Herget-Rosenthal S, Klein T, Marggraf G, Hirsch T, Jakob HG, Philipp T, Kribben A. Modulation and source of procalcitonin in reduced renal function and renal replacement therapy. Scand J Immunol. 2005;61:180\u20136.","journal-title":"Scand J Immunol"},{"key":"1639_CR25","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/ndt\/16.5.975","volume":"16","author":"S Herget-Rosenthal","year":"2001","unstructured":"Herget-Rosenthal S, Marggraf G, Pietruck F, Husing J, Strupat M, Philipp T, Kribben A. Procalcitonin for accurate detection of infection in haemodialysis. Nephrol Dial Transplant. 2001;16:975\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1639_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3109\/00365510902993663","volume":"69","author":"M Montagnana","year":"2009","unstructured":"Montagnana M, Lippi G, Tessitore N, Salvagno GL, Danese E, Targher G, et al. Procalcitonin values after dialysis is closely related to type of dialysis membrane. Scand J Clin Lab Invest. 2009;69:703\u20137.","journal-title":"Scand J Clin Lab Invest"},{"key":"1639_CR27","doi-asserted-by":"publisher","first-page":"620","DOI":"10.2215\/CJN.09060914","volume":"10","author":"MA Fahim","year":"2015","unstructured":"Fahim MA, Hayen A, Horvath AR, Dimeski G, Coburn A, Johnson DW, et al. N-terminal pro-b-type natriuretic peptide variability in stable dialysis patients. Clin J Am Soc Nephrol. 2015;10:620\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1639_CR28","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1373\/clinchem.2013.216978","volume":"60","author":"KM Aakre","year":"2014","unstructured":"Aakre KM, Roraas T, Petersen PH, Svarstad E, Sellevoll H, Skadberg O, et al. Weekly and 90-minute biological variations in cardiac troponin t and cardiac troponin i in hemodialysis patients and healthy controls. Clin Chem. 2014;60:838\u201347.","journal-title":"Clin Chem"},{"key":"1639_CR29","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1373\/clinchem.2013.209353","volume":"59","author":"KM Aakre","year":"2013","unstructured":"Aakre KM, Roraas T, Petersen PH, Svarstad E, Saele K, Sandberg S. Week-to-week biological variation in the n-terminal prohormone of brain natriuretic peptide in hemodialysis patients and healthy individuals. Clin Chem. 2013;59:1813\u20134.","journal-title":"Clin Chem"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-018-1639-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1639-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1639-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T23:29:59Z","timestamp":1661988599000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-018-1639-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,8]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["1639"],"URL":"https:\/\/doi.org\/10.1007\/s10157-018-1639-2","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,8]]},"assertion":[{"value":"23 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"NJ has received financial support for this clinical research from Roche Diagnostics. There are no conflicts of interest for the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee at which the studies were conducted (IRB approval number 13\u201364) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}